CARE Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for CARE Trial.

Objective[edit | edit source]

To assess if pravastatin would reduce the sum of fatal coronary artery disease (CAD) and nonfatal myocardial infarction (MI) in patients who had a previous MI and a total cholesterol value < 240 mg/dl.

Methods[edit | edit source]

Cholesterol and Recurrent Events trial was a double blinded, randomized study wherein 4159 patients with a history of a myocardial infarction in the previous two years who had a total cholesterol value < 240 mg/dl were enrolled and treated with either 40 mg pravastatin or a placebo.

Results[edit | edit source]

The following results were obtained after a median follow-up time of 5 years:

• Reduced combined end point of coronary death and nonfatal MI (10.2 versus 13.2 percent)
• Reduced need for revascularization with CABG or PTCA (14.1 versus 18.8 percent)
• Reduced frequency of stroke (2.6 versus 3.8 percent) and of stroke plus transient ischemic attacks (4.4 versus 6.0 percent)^[1][2]

References[edit | edit source]